{"id":"dose-d1-of-interleukin-2","safety":{"commonSideEffects":[{"rate":"null","effect":"Flu-like symptoms"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Interleukin-2 is a cytokine that plays a crucial role in the immune response, particularly in the activation and proliferation of T-cells. It is used to treat various types of cancer, including melanoma and renal cell carcinoma.","oneSentence":"Interleukin-2 stimulates T-cell proliferation and activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:34:34.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT01671774","phase":"PHASE1","title":"Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-10-16","conditions":"CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus","enrollment":29},{"nctId":"NCT03875079","phase":"PHASE1","title":"A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-24","conditions":"Metastatic Melanoma","enrollment":83},{"nctId":"NCT05530200","phase":"PHASE2","title":"PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2022-09","conditions":"Metastatic Solid Tumor","enrollment":56},{"nctId":"NCT01840046","phase":"PHASE1, PHASE2","title":"Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2012-11","conditions":"Alopecia Areata","enrollment":4},{"nctId":"NCT04892498","phase":"PHASE2","title":"Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2021-05-30","conditions":"Advanced Refractory Solid Tumors","enrollment":66},{"nctId":"NCT01862120","phase":"PHASE2","title":"Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-06-27","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT03778619","phase":"PHASE1, PHASE2","title":"MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin","status":"UNKNOWN","sponsor":"GC Cell Corporation","startDate":"2018-11-28","conditions":"Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":9},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Dose D1 of interleukin-2","genericName":"Dose D1 of interleukin-2","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interleukin-2 stimulates T-cell proliferation and activation. Used for Melanoma, Renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}